Helsinki, Finland, 10.11.2026
Rokote Laboratories Finland Oy and GlobeVAC Oy have entered into a strategic collaboration to evaluate the application of GlobeVAC’s stabilization technology to the FINVAC intranasal vaccine platform. The objective of the collaboration is to enable ambient-temperature storage and distribution of FINVAC-based vaccine products, reducing reliance on cold-chain logistics and improving global vaccine accessibility.
Under the collaboration, the companies will assess whether GlobeVAC’s technology can preserve the stability, quality, and performance of vaccines developed using the FINVAC platform under non refrigerated conditions. The work will initially focus on formulation development and stability testing.
The ability to distribute vaccines without strict temperature-controlled storage requirements could substantially simplify global vaccine supply chains, reduce logistics costs, and improve access to vaccination in regions where cold-chain infrastructure is limited.
“At Rokote Laboratories, our mission is to develop effective intranasal vaccines that can be deployed efficiently across the world,” said Dr. Erkko Ylösmäki, CEO of Rokote Laboratories Finland Oy. “Combining the FINVAC platform with GlobeVAC’s stabilization technology could
provide an important opportunity to improve vaccine accessibility and facilitate distribution in both developed and resource-limited settings.”
Dr. Manlio Fusciello, CEO of GlobeVAC Oy, commented: “We are excited to collaborate with Rokote Laboratories and evaluate how our stabilization technology can support the FINVAC platform. Removing cold-chain constraints remains one of the most important opportunities to improve global vaccine deployment, and we look forward to generating data together.” The collaboration reflects the companies’ shared commitment to addressing one of the major challenges in global immunization: ensuring that innovative vaccines can be stored, transported, and delivered efficiently to populations worldwide.
About Rokote Laboratories Finland Oy
Rokote Laboratories Finland Oy is a Finnish clinical-stage biotechnology company developing the FINVAC intranasal vaccine platform. FINVAC is designed to enable efficient vaccine development, manufacturing, and deployment while inducing robust mucosal and systemic immune responses and improving the accessibility of next-generation vaccines.
About GlobeVAC Oy
GlobeVAC Oy is a Finnish biotechnology company developing stabilization technologies aimed at improving the thermal stability, storage, and distribution of vaccines and other biological products.
Media Contact
Rokote Laboratories Finland Oy
Erkko Ylösmäki, CEO
erkko.ylosmaki@rokote.com
+358 40583 6604
GlobeVAC Oy
Manlio Fusciello, CEO
manlio@globe-vac.com
+358469345807